JP2019528285A5 - - Google Patents

Info

Publication number

JP2019528285A5

JP2019528285A5 JP2019509555A JP2019509555A JP2019528285A5 JP 2019528285 A5 JP2019528285 A5 JP 2019528285A5 JP 2019509555 A JP2019509555 A JP 2019509555A JP 2019509555 A JP2019509555 A JP 2019509555A JP 2019528285 A5 JP2019528285 A5 JP 2019528285A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

use according

human patient

disease

crohn

Prior art date

2017-08-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 208000011231 Crohn disease Diseases 0.000 claims description 16
• 230000009266 disease activity Effects 0.000 claims description 8
• 230000000694 effects Effects 0.000 claims description 5
• 206010016717 Fistula Diseases 0.000 claims description 4
• 230000003890 fistula Effects 0.000 claims description 4
• 230000006698 induction Effects 0.000 claims description 4
• 230000005764 inhibitory process Effects 0.000 claims description 4
• 208000024891 symptom Diseases 0.000 claims description 4
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
• 239000012472 biological sample Substances 0.000 claims description 3
• 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
• 102100032752 C-reactive protein Human genes 0.000 claims description 2
• 206010067671 Disease complication Diseases 0.000 claims description 2
• 206010061818 Disease progression Diseases 0.000 claims description 2
• 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 2
• 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 2
• 101150091651 MICB gene Proteins 0.000 claims description 2
• 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 claims description 2
• 238000003556 assay Methods 0.000 claims description 2
• 230000005750 disease progression Effects 0.000 claims description 2
• 230000002550 fecal effect Effects 0.000 claims description 2
• 238000003205 genotyping method Methods 0.000 claims description 2
• 238000001990 intravenous administration Methods 0.000 claims description 2
• 238000012423 maintenance Methods 0.000 claims description 2
• 239000002773 nucleotide Substances 0.000 claims description 2
• 125000003729 nucleotide group Chemical group 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 29
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 description 21
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 229960003824 ustekinumab Drugs 0.000 description 1